• 岚山区拨付595 万元补助农村危房改造 2019-06-09
  • 拉萨市海拔4300米以下再无“无树村 无树户” 2019-06-09
  • 紫光阁中共中央国家机关工作委员会 2019-06-08
  • 河北唐山:赵滩葡萄好 2019-06-08
  • 女性之声——全国妇联 2019-06-08
  • 我老张工经历过中国计划经济时代,实践过计划经济,岂能不知计划经济?!现在的市场经济,我也有了实践感受。比较之,深感计划经济是适合社会主义的,而市场经济是不适合社 2019-06-08
  • 坐观光巴士 小小代言人带你游广州 2019-06-07
  • 钱江晚报:维权手段不升级,流氓APP难消停 2019-06-07
  • 中华龙舟大赛福州站收官 黑马异军突起摘大满贯 2019-06-07
  • (Dos sesiones) Enfoque de China Dos sesiones históricas fijan el rumbo para nueva época Spanish.xinhuanet.com 2019-06-06
  • 海岸旅行地中国国家地理网 2019-06-06
  • 西部网(陕西新闻网)www.cnwest.com 2019-06-06
  • 库里:我从未幻想过我们能够进行总冠军游行 2019-06-05
  • 骞垮窞甯傜綉缁滃晢鍝佷氦鏄撲笌鏈嶅姟鐩戠骞冲彴 2019-06-05
  • 长城新媒体集团有限公司承德记者站招聘公告 2019-06-05
  •    
    白小姐开状         Site Map |
     
     
     
    Guilin Pharma announces partnership with Idis for controlled access to Injectable Artesunate.
    Date: Oct.30.2013
     
    29th October, 2013, London and Shanghai, Guilin Pharma and Idis announced today that Artesun® (artesunate for injection) 60mg vials are now available to patients outside of those countries in which it is either commercially available or supplied through the World Health Organization. Controlled, ethical access is provided through an Idis Access Program, allowing physicians around the world to obtain access for their patients to investigational drugs or drugs not approved in their country.
     
    Administered intravenously or intramuscularly, Artesun® is approved in China (and recommended by World Health Organization) for the treatment of severe malaria caused by Plasmodium falciparum, in adults and children. It is also listed as a WHO Prequalified Medicinal Product.
     
    "We are delighted to be implementing this secure supply route for patients in need around the world" said Mr Yu Zhemin, Chairman of Guilin Pharmaceutical Co., Ltd. "This programme allows us to expand access, safely and ethically outside of countries where it is currently available. Working with Idis to achieve this means that prescribers and patients can have regulated access to this potentially life-saving medicine白小姐开状 when they need it.”
     
    Charles Simmons, President of Established Brands at Idis said of the partnership “Until now there has not been a secure, centralized way to access injectable artesunate except in a few countries where it is commercially available or those served by WHO. Patients are at the heart of what we do at Idis and we are delighted to partner with Guilin to provide this vital bridge so that no patient is left untreated".
     
    Licensed healthcare professionals outside of China, Indonesia, Thailand, Myanmar, Pakistan, Peru and the African Continent with patients who might benefit from injectable artesunate should contact Idis directly using the following contact details:
     
    Idis UK & Eire Enquiries
    Tel: +44 (0) 1932 824 100
    Fax: +44 (0) 1932 824 300
     
    Idis Rest of the World Enquiries
    Tel: +44 (0) 1932 824 123
    Fax: +44 (0) 1932 824 323
     

     
    About Malaria
    Malaria is a mosquito-borne disease caused by a parasite. People with malaria often experience fever, chills, and flu-like illness. Left untreated, they may develop severe complications and die. In 2010 an estimated 219 million cases of malaria occurred worldwide and 660,000 people died, most (91%) in the African Region (Source: CDC website, August 2013).
     
    About Guilin Pharmaceutical Co., Ltd
    Established in 1950’s, Guilin Pharma is a professional pharmaceutical enterprise specialised in researching, manufacturing and marketing of pharmaceutical products. The company produces more than 200 chemical medicines in different dosage forms such as tablets, capsules, and injections.
    As the first Chinese pharmaceutical manufacturer approved by the World Health Organization, Guilin Pharma is also China’s largest artemisinin based anti-malarial drug producer with the world’s most integrated artemisinin Industry value chain
    So far, products of Guilin Pharma have been registered and marketed in more than 30 countries internationally. As a World Health Organization approved antimalarial producer, Guilin Pharma has supplied over 200,000,000 oral treatments of its artemisinin based anti-malaria drugs to the world malaria campaign.
    Guilin Pharma also works with international NGOs, academic institutions and the local malaria control programs on training project to improve the medical skills of local medical staff, so as to reduce malaria mortality in African children.
    Guilin Pharma believes in a management philosophy of “quality comes first”. It continuously improves its production process with international Good Manufacturing Practices Standards so as to supply high quality pharmaceuticals to people who use its products.
     
    About Idis
    Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world. 
     
    Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product’s lifecycle from pre-approval to market exit, and in times of unexpected production shortages.
    The company’s European headquarters are located in Weybridge, United Kingdom, and North American headquarters are located in Princeton, NJ.
     
    For more information about Idis please visit www.idispharma.com.
     

    This site is published by Guilin Pharmaceutical (Shanghai) Corporation,        which is solely responsible for its content. All rights reserved.

    © Guilin Pharmaceutical (Shanghai) Co., Ltd. 2017.

  • 岚山区拨付595 万元补助农村危房改造 2019-06-09
  • 拉萨市海拔4300米以下再无“无树村 无树户” 2019-06-09
  • 紫光阁中共中央国家机关工作委员会 2019-06-08
  • 河北唐山:赵滩葡萄好 2019-06-08
  • 女性之声——全国妇联 2019-06-08
  • 我老张工经历过中国计划经济时代,实践过计划经济,岂能不知计划经济?!现在的市场经济,我也有了实践感受。比较之,深感计划经济是适合社会主义的,而市场经济是不适合社 2019-06-08
  • 坐观光巴士 小小代言人带你游广州 2019-06-07
  • 钱江晚报:维权手段不升级,流氓APP难消停 2019-06-07
  • 中华龙舟大赛福州站收官 黑马异军突起摘大满贯 2019-06-07
  • (Dos sesiones) Enfoque de China Dos sesiones históricas fijan el rumbo para nueva época Spanish.xinhuanet.com 2019-06-06
  • 海岸旅行地中国国家地理网 2019-06-06
  • 西部网(陕西新闻网)www.cnwest.com 2019-06-06
  • 库里:我从未幻想过我们能够进行总冠军游行 2019-06-05
  • 骞垮窞甯傜綉缁滃晢鍝佷氦鏄撲笌鏈嶅姟鐩戠骞冲彴 2019-06-05
  • 长城新媒体集团有限公司承德记者站招聘公告 2019-06-05
  • 赫塔菲ued官网 黑龙江11选5开奖信息 中国到南安普敦 兰斯特怎么打 维戈塞尔塔西甲排名 超级高速公路之王APP 南特和里尔 西班牙瓦伦西亚产区 电脑版绝地求生下载要钱吗 王牌5PK送彩金